|
1
|
Taketomi A, Shirabe K, Muto J, Yoshiya S,
Motomura T, Mano Y, Ikegami T, Yoshizumi T, Sugio K and Maehara Y:
A rare point mutation in the Ras oncogene in hepatocellular
carcinoma. Surg Today. 43:289–292. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rossi L, Zoratto F, Papa A, Iodice F,
Minozzi M, Frati L and Tomao S: Current approach in the treatment
of hepatocellular carcinoma. World J Gastrointest Oncol. 2:348–359.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Poggi G, Montagna B, Melchiorre F,
Quaretti P, Delmonte A, Riccardi A, Tagliaferri B, Sottotetti F, Di
Cesare P, Stella MG, et al: Hepatic intra-arterial cetuximab in
combination with 5-fluorouracil and cisplatin as salvage treatment
for sorafenib-refractory hepatocellular carcinoma. Anticancer Res.
31:3927–3933. 2011.PubMed/NCBI
|
|
4
|
Dhanasekaran R, Limaye A and Cabrera R:
Hepatocellular carcinoma: Current trends in worldwide epidemiology,
risk factors, diagnosis, and therapeutics. Hepat Med. 4:19–37.
2012.PubMed/NCBI
|
|
5
|
Corey KE and Pratt DS: Current status of
therapy for hepatocellular carcinoma. Therap Adv Gastroenterol.
2:45–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu AX, Stuart K, Blaszkowsky LS,
Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P,
Meyerhardt JA, Horgan K, et al: Phase 2 study of cetuximab in
patients with advanced hepatocellular carcinoma. Cancer.
110:581–589. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mittal S and El-Serag HB: Epidemiology of
hepatocellular carcinoma: Consider the population. J Clin
Gastroenterol. 47(Suppl): S2–S6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alacacioglu A, Somali I, Simsek I,
Astarcioglu I, Ozkan M, Camci C, Alkis N, Karaoglu A, Tarhan O,
Unek T, et al: Epidemiology and survival of hepatocellular
carcinoma in Turkey: Outcome of multicenter study. Jpn J Clin
Oncol. 38:683–688. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dogan E, Yalcin S, Koca D and Olmez A:
Clinicopathological characteristics of hepatocellular carcinoma in
Turkey. Asian Pac J Cancer Prev. 13:2985–2990. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Can A, Dogan E, Bayoglu IV, Tatli AM,
Besiroglu M, Kocer M, Dulger AC, Uyeturk U, Kivrak D, Orakci Z, et
al: Multicenter epidemiologic study on hepatocellular carcinoma in
Turkey. Asian Pac J Cancer Prev. 15:2923–2927. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ye H, Zhang C, Wang BJ, Tan XH, Zhang WP,
Teng Y and Yang X: Synergistic function of Kras mutation and HBx in
initiation and progression of hepatocellular carcinoma in mice.
Oncogene. 33:5133–5138. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Adjei AA: Blocking oncogenic Ras signaling
for cancer therapy. J Natl Cancer Inst. 93:1062–1074. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim JH, Kim HY, Lee YK, Yoon YS, Xu WG,
Yoon JK, Choi SE, Ko YG, Kim MJ, Lee SJ, et al: Involvement of
mitophagy in oncogenic K-Ras-induced transformation: Overcoming a
cellular energy deficit from glucose deficiency. Autophagy.
7:1187–1198. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Asnacios A, Fartoux L, Romano O, Tesmoingt
C, Louafi SS, Mansoubakht T, Artru P, Poynard T, Rosmorduc O,
Hebbar M, et al: Gemcitabine plus oxaliplatin (GEMOX) combined with
cetuximab in patients with progressive advanced stage
hepatocellular carcinoma: Results of a multicenter phase 2 study.
Cancer. 112:2733–2739. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vallée A, Le Loupp AG and Denis MG:
Efficiency of the TheraScreen® RGQ PCR kit for the detection of
EGFR mutations in non-small cell lung carcinomas. Clin Chim Acta.
429:8–11. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adams JA, Post KM, Bilbo SA, Wang X, Sen
JD, Cornwell AJ, Malek AJ and Cheng L: Performance evaluation
comparison of 3 commercially available PCR-based KRAS mutation
testing platforms. Appl Immunohistochem Mol Morphol. 22:231–235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang SC, Denne J, Zhao L, Horak C, Green
G, Khambata-Ford S, Bray C, Celik I, Van Cutsem E and Harbison C:
Comparison of KRAS genotype: TheraScreen assay vs. LNA-mediated
qPCR clamping assay. Clin Colorectal Cancer. 12:195–203.e2. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sanoff HK, Bernard S, Goldberg RM, Morse
MA, Garcia R, Woods L, Moore DT and O'Neil BH: Phase II study of
capecitabine, oxaliplatin and cetuximab for advanced hepatocellular
carcinoma. Gastrointest Cancer Res. 4:78–83. 2011.PubMed/NCBI
|
|
20
|
Colombino M, Sperlongano P, Izzo F,
Tatangelo F, Botti G, Lombardi A, Accardo M, Tarantino L, Sordelli
I, Agresti M, et al: BRAF and PIK3CA genes are somatically mutated
in hepatocellular carcinoma among patients from South Italy. Cell
Death Dis. 3:e2592012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lord PG, Hardaker KJ, Loughlin JM, Marsden
AM and Orton TC: Point mutation analysis of ras genes in
spontaneous and chemically induced C57Bl/10J mouse liver tumours.
Carcinogenesis. 13:1383–1387. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weihrauch M, Benick M, Lehner G, Wittekind
M, Bader M, Wrbitzk R and Tannapfel A: High prevalence of K-ras-2
mutations in hepatocellular carcinomas in workers exposed to vinyl
chloride. Int Arch Occup Environ Health. 74:405–410. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weihrauch M, Benicke M, Lehnert G,
Wittekind C, Wrbitzky R and Tannapfel A: Frequent k-ras-2 mutations
and p16(INK4A)methylation in hepatocellular carcinomas in workers
exposed to vinyl chloride. Br J Cancer. 84:982–989. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bai F, Nakanishi Y, Takayama K, Pei XH,
Inoue K, Harada T, Izumi M and Hara N: Codon 64 of K-ras gene
mutation pattern in hepatocellular carcinomas induced by bleomycin
and 1-nitropyrene in A/J mice. Teratog Carcinog Mutagen. 23(Suppl
1): 161–170. 2003. View Article : Google Scholar
|
|
25
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yarom N and Jonker DJ: The role of the
epidermal growth factor receptor in the mechanism and treatment of
colorectal cancer. Discov Med. 11:95–105. 2011.PubMed/NCBI
|
|
27
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Garassino MC, Borgonovo K, Rossi A,
Mancuso A, Martelli O, Tinazzi A, Di Cosimo S, La Verde N, Sburlati
P, Bianchi C, et al: Biological and clinical features in predicting
efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors: A systematic review and meta-analysis. Anticancer Res.
29:2691–2701. 2009.PubMed/NCBI
|
|
29
|
Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu
IC, Lin SR and Wang JY: Activating KRAS mutations and
overexpression of epidermal growth factor receptor as independent
predictors in metastatic colorectal cancer patients treated with
cetuximab. Ann Surg. 251:254–260. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Folprecht G, Gruenberger T, Bechstein W,
Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J,
Lang H, Trarbach T, et al: Survival of patients with initially
unresectable colorectal liver metastases treated with
FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary
concept (CELIM study). Ann Oncol. 25:1018–1025. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ji JH, Park SH, Lee J, Kim TW, Hong YS,
Kim KP, Kim SY, Baek JY, Kang HJ, Shin SJ, et al: Prospective phase
II study of neoadjuvant FOLFOX6 plus cetuximab in patients with
colorectal cancer and unresectable liver-only metastasis. Cancer
Chemother Pharmacol. 72:223–230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang Y, Kimchi ET, Staveley-O'Carroll KF,
Cheng H and Ajani JA: Assessment of K-ras mutation: A step toward
personalized medicine for patients with colorectal cancer. Cancer.
115:3609–3617. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rubovszky G, Láng I, Ganofszky E, Horváth
Z, Juhos E, Nagy T, Szabó E, Szentirmay Z, Budai B and Hitre E:
Cetuximab, gemcitabine and capecitabine in patients with inoperable
biliary tract cancer: A phase 2 study. Eur J Cancer. 49:3806–3812.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shi M, Shi H, Ji J, Cai Q, Chen X, Yu Y,
Liu B, Zhu Z and Zhang J: Cetuximab inhibits gastric cancer growth
in vivo, independent of KRAS status. Curr Cancer Drug Targets.
14:217–224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun PL, Li B and Ye QF: Effect of
neoadjuvant cetuximab, capecitabine and radiotherapy for locally
advanced rectal cancer: Results of a phase II study. Int J
Colorectal Dis. 27:1325–1332. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Uribe P and Gonzalez S: Epidermal growth
factor receptor (EGFR) and squamous cell carcinoma of the skin:
Molecular bases for EGFR-targeted therapy. Pathol Res Pract.
207:337–342. 2011. View Article : Google Scholar : PubMed/NCBI
|
